TAKEDA PHARMACEUTICAL COMPANY LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4,089 JPY | -0.02% |
|
+0.49% | +0.86% |
| Apr. 26 | EU Panel Backs Approval of Takeda’s Colorectal Cancer Drug | MT |
| Apr. 26 | Hutchmed notes CHMP's positive opinion for fruiquintinib approval | AN |
Presenter SpeechKen Cacciatore (Analysts)Okay. Great. Thanks, everyone, for joining the Takeda...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Takeda Pharmaceutical Company Limited specializes in the development, manufacturing and marketing of pharmaceutical products especially for metabolic and cardiovascular diseases, cancers and central nervous systems troubles. The activity is organized around 2 areas:
- sale of drugs and consumer care products;
- services.
Net sales are distributed geographically as follows: Japan (17.5%), Asia (5%), the United States (49%), Europe and Canada (20.8%), Latin America (3.8%), Russia and CIS (1.8%) and other (2.1%).
Sector
Pharmaceuticals
Calendar
2024-05-08
- Q4 2023 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
4,089
JPY
Average target price
4,779
JPY
Spread / Average Target
+16.88%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +0.86% | 40.76B | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- 4502 Stock
- News Takeda Pharmaceutical Company Limited
- Transcript : Takeda Pharmaceutical Company Limited Presents at 42nd Annual Cowen Health Care Conference, Mar-08-2022 02
